Apotex Research, an Indian subsidiary of global pharmaceutical company Apotex Inc., headquartered in Toronto Canada has announced a significant investment which will further expand its footprint in India. It set up its Global Business Services office in Mumbai to provide centralized service delivery for various areas including Medical, Regulatory, Quality, Manufacturing, Administrative and Commercial functions for Apotex globally. In addition, the move will create 200 job openings.
The new office, located in Godrej & Boyce Business District, Vikhroli spans over 42,000 square feet and has been designed to maximize collaboration and employee engagement.
In 2004, Apotex Research and its sister company, Apotex Pharmachem were established in Bengaluru. Over the last 13 years, it evolved into one of Apotex’s global strategic R&D and manufacturing centres with over 2,500 employees. Operations include API & Formulation R&D, Clinical Research, API and Finished Dose Manufacturing. The state-of the art campus in Bengaluru supplies products to the US, Canada, EU and Australia.
“Mumbai is the commercial hub of India with a strong pharmaceutical presence including key talent, so it is good strategic location for continued growth of Apotex’s business in India. The Global Business Services operation will make a significant contribution to Apotex’s future business growth,” said Dr. Rav Kumar, Managing Director, Apotex Research.
According to Dr. Jeremy B. Desai, CEO & President, Apotex Inc., India continues to be one of our global strategic centres and I am thrilled to announce this further investment. The Global Business Services function will be a key contributor to our business and will support our purpose of improving access to medicines for millions of patients by providing affordable, innovative and high-quality solutions.
“We have seen a promising growth path in India and the Global Business Services operations strengthens this path. I look forward to a steady incline supported by highly capable talent and our core values in a quality conscious environment,” said Yoganjaneya Reddy, VP & Site Head, Apotex Pharmachem India.
Apotex is Canada’s largest privately held pharmaceutical company with a global presence in more than 45 countries with more than 11,000 employees. With its worldwide manufacturing sites, it can manufacture up to 25 billion dosages per year. It produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. The company will spend $2 billion over the next 10 years on research and development.
Apotex increases investment, create more than 200 high-calibre jobs
